InsiderTrades.com logo
David Soergel net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

David Soergel Biography and Net Worth

Insider of Madrigal Pharmaceuticals

Dr. Soergel joins Madrigal from Novartis, where he served as the Executive Vice President and Global Head of Cardiovascular, Renal, and Metabolism Development, overseeing 10 late-stage development programs in 2024. At Novartis, Dave led teams that designed and implemented evidence generation programs supporting the expansion of Entresto’s indications and uses. Additionally, he advanced novel medicines to approval for cardiovascular and renal diseases, including Leqvio, Fabhalta and Vanrafia, and served as the development lead for the acquisitions of the Medicines Company and Chinook Therapeutics. Prior to Novartis, Dr. Soergel held leadership roles at biotechnology companies, including Senior Vice President of Clinical Development and Chief Medical Officer at Trevena, where he was responsible for the development of novel treatments for pain and other conditions. He began his career in early-stage clinical development and translational medicine at GlaxoSmithKline. Dr. Soergel trained in pediatrics, pediatric cardiology, and heart failure and transplant at Johns Hopkins Hospital and the Children’s Hospital of Philadelphia.

What is David Soergel's net worth?

The estimated net worth of David Soergel is at least $5.67 million as of May 18th, 2026. Soergel owns 11,075 shares of Madrigal Pharmaceuticals stock worth more than $5,668,407 as of May 19th. This net worth approximation does not reflect any other investments that Soergel may own. Learn More about David Soergel's net worth.

How do I contact David Soergel?

The corporate mailing address for Soergel and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on David Soergel's contact information.

Has David Soergel been buying or selling shares of Madrigal Pharmaceuticals?

During the last quarter, David Soergel has sold $435,419.60 of Madrigal Pharmaceuticals stock. Most recently, David Soergel sold 844 shares of the business's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $515.90, for a transaction totalling $435,419.60. Following the completion of the sale, the insider now directly owns 11,075 shares of the company's stock, valued at $5,713,592.50. Learn More on David Soergel's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Kenneth Bate (Director), Fred Craves (Director), James Daly (Director), Mardi Dier (Executive Vice President, Chief Financial Officer), Paul Friedman (Director), Carole Huntsman (Chief Commercial Officer), Shannon Kelley (General Counsel), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), David Soergel (Insider), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 3 times. They purchased a total of 165,683 shares worth more than $61,921,142.32. During the last twelve months, insiders at the biopharmaceutical company sold shares 38 times. They sold a total of 442,531 shares worth more than $182,790,868.67. The most recent insider tranaction occured on May, 18th when insider David Soergel sold 844 shares worth more than $435,419.60. Insiders at Madrigal Pharmaceuticals own 17.6% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 5/18/2026.

David Soergel Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2026Sell844$515.90$435,419.6011,075View SEC Filing Icon  
See Full Table

David Soergel Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows David Soergel's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $511.82
Low: $508.86
High: $528.99

50 Day Range

MA: $501.46
Low: $431.53
High: $546.89

2 Week Range

Now: $511.82
Low: $265.00
High: $615.00

Volume

258,876 shs

Average Volume

280,717 shs

Market Capitalization

$11.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A